| Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents E Asín-Prieto, A Rodríguez-Gascón, A Isla Journal of Infection and Chemotherapy 21 (5), 319-329, 2015 | 295 | 2015 |
| Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic … E Asín-Prieto, A Rodríguez-Gascón, IF Trocóniz, A Soraluce, J Maynar, ... Journal of Antimicrobial Chemotherapy 69 (1), 180-189, 2014 | 76 | 2014 |
| Hyaluronic acid coating of gold nanoparticles for intraocular drug delivery: Evaluation of the surface properties and effect on their distribution PS Apaolaza, M Busch, E Asin-Prieto, K Peynshaert, R Rathod, K Remaut, ... Experimental eye research 198, 108151, 2020 | 56 | 2020 |
| Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria E Asín, A Isla, A Canut, AR Gascón International journal of antimicrobial agents 40 (4), 313-322, 2012 | 49 | 2012 |
| Population pharmacokinetics of daptomycin in critically ill patients A Soraluce, E Asín-Prieto, A Rodríguez-Gascón, H Barrasa, J Maynar, ... International journal of antimicrobial agents 52 (2), 158-165, 2018 | 36 | 2018 |
| Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases A Isla, A Canut, J Arribas, E Asín-Prieto, A Rodríguez-Gascón European Journal of Clinical Microbiology & Infectious Diseases 35, 511-519, 2016 | 26 | 2016 |
| Population pharmacokinetic models for cefuroxime and metronidazole used in combination as prophylactic agents in colorectal surgery: Model-based evaluation of standard dosing … E Asín-Prieto, A Soraluce, IF Trocóniz, EC Cimarras, JS de Ugarte Sobrón, ... International journal of antimicrobial agents 45 (5), 504-511, 2015 | 23 | 2015 |
| Novel population pharmacokinetic model for linezolid in critically ill patients and evaluation of the adequacy of the current dosing recommendation A Soraluce, H Barrasa, E Asín-Prieto, JÁ Sánchez-Izquierdo, J Maynar, ... Pharmaceutics 12 (1), 54, 2020 | 22 | 2020 |
| Predicting pediatric age-matched weight and body mass index SKB Sy, E Asin-Prieto, H Derendorf, E Samara The AAPS journal 16, 1372-1379, 2014 | 19 | 2014 |
| A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis JWS Cattrall, E Asín-Prieto, J Freeman, IF Troconiz, A Kirby European Journal of Clinical Microbiology & Infectious Diseases 38, 2311-2321, 2019 | 17 | 2019 |
| Zein nanoparticles improve the oral bioavailability of curcumin in Wistar rats A Brotons-Canto, CJ González-Navarro, AG Gil, E Asin-Prieto, MJ Saiz, ... Pharmaceutics 13 (3), 361, 2021 | 16 | 2021 |
| Population pharmacokinetics of levetiracetam and dosing evaluation in critically ill patients with normal or augmented renal function I Bilbao-Meseguer, H Barrasa, E Asín-Prieto, A Alarcia-Lacalle, ... Pharmaceutics 13 (10), 1690, 2021 | 12 | 2021 |
| A quantitative systems pharmacology model for the key interleukins involved in Crohn's disease V Balbas-Martinez, E Asin-Prieto, ZP Parra-Guillen, IF Troconiz Journal of Pharmacology and Experimental Therapeutics 372 (3), 299-307, 2020 | 12 | 2020 |
| Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model SKB Sy, R Malmberg, A Matsushima, E Asin-Prieto, B Rosenkranz, ... International journal of antimicrobial agents 45 (4), 413-419, 2015 | 12 | 2015 |
| Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study I Bilbao-Meseguer, H Barrasa, A Rodríguez-Gascón, E Asín-Prieto, ... Journal of Intensive Care 10 (1), 21, 2022 | 7 | 2022 |
| Predicting circulating biomarker response and its impact on the survival of advanced melanoma patients treated with adjuvant therapy I Irurzun-Arana, E Asín-Prieto, S Martín-Algarra, IF Trocóniz Scientific Reports 10 (1), 1-13, 2020 | 7 | 2020 |
| The long neglected player: modeling tumor uptake to guide optimal dosing L Ruiz-Cerdá, E Asín-Prieto, ZP Parra-Guillen, IF Trocóniz Clinical Cancer Research 24 (14), 3236-3238, 2018 | 6 | 2018 |
| Colo-Pro: a pilot randomised controlled trial to compare standard bolus-dosed cefuroxime prophylaxis to bolus-continuous infusion–dosed cefuroxime prophylaxis for the … A Kirby, E Asín-Prieto, FA Burns, D Ewin, K Fatania, M Kailavasan, ... European Journal of Clinical Microbiology & Infectious Diseases 38, 357-363, 2019 | 4 | 2019 |
| Population pharmacokinetics of levetiracetam and dosing evaluation in critically ill patients with normal or augmented renal function. Pharmaceutics. 2021; 13 (10): 1690 I Bilbao‑Meseguer, H Barrasa, E Asín‑Prieto, A Alarcia‑Lacalle, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | 2 | 2021 |
| Immune network for viral hepatitis B: Topological representation E Asin-Prieto, ZP Parra-Guillen, JDG Mantilla, J Vandenbossche, ... European Journal of Pharmaceutical Sciences 136, 104939, 2019 | 2 | 2019 |
Zinnia Patricia Parra GuillénUniversity of NavarraVerified email at unav.es
